Post by
stockfy on Mar 08, 2022 3:51am
VMD: Top line YoY growth (core business), 4X the adj. EBITDA
YoY growth for the core business continued for another quarter in a row with VMD reporting 11% YoY revenue growth.
VMD also maintained a fortress balance sheet with a strong net cash position of $24 million.
With adj. EBITDA at almost $30 million for 2021, VMD's Enterprise Value currently is only 4 times its adj. EBITDA.
Outlook remains bright and growth will continue in the next quarters:
"We believe organic growth trends are emerging during the periods following COVID surges," said Casey Hoyt, Viemed's CEO. "Following the Delta variant surge during the third quarter, our sales and clinical teams returned to the field in the fourth quarter eager to serve the strong demand in the market. As a result, we finished the quarter with record setting core revenues and active patient count. As we look forward to the upcoming year, we are excited to meet this demand with the innovative service offerings, which we invested in during the pandemic.”
Comment by
JackLambert on Mar 08, 2022 7:46am
Good post. In spite of much of the hysterical panty-wetting one reads on this board there is nothing wrong with this company or it's market place. Other than the pandemic. And we are very well positioned for rapid recovery.